The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies

@article{Mller1998TheFC,
  title={The first constant domain (CH1 and CL) of an antibody used as heterodimerization domain for bispecific miniantibodies},
  author={K. M. M{\"u}ller and K. Arndt and W. Strittmatter and A. Pl{\"u}ckthun},
  journal={FEBS Letters},
  year={1998},
  volume={422}
}
  • K. M. Müller, K. Arndt, +1 author A. Plückthun
  • Published 1998
  • Chemistry, Medicine
  • FEBS Letters
  • Bispecific miniantibodies were constructed by genetically fusing the CH1 domain of an IgG1 to the C‐terminus of a single‐chain Fv fragment (scFv‐425), specific for the EGF receptor, and fusing the CL domain of a kappa light chain to the C‐terminus of a scFv specific for CD2 (scFv‐M1). An efficient dicistronic gene arrangement for functional expression in Escherichia coli was constructed. Immunoblots demonstrated correct domain assembly and the formation of the natural CH1‐CL disulfide bridge… CONTINUE READING
    76 Citations
    Fab Chains As an Efficient Heterodimerization Scaffold for the Production of Recombinant Bispecific and Trispecific Antibody Derivatives1
    • 58
    • Highly Influenced
    • PDF
    Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
    • 34
    Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    • 170
    An efficient route to the production of an IgG-like bispecific antibody.
    • 35
    • PDF

    References

    SHOWING 1-10 OF 42 REFERENCES
    Design and production of novel tetravalent bispecific antibodies
    • 188
    "Diabodies": small bivalent and bispecific antibody fragments.
    • 822
    • PDF
    New protein engineering approaches to multivalent and bispecific antibody fragments.
    • A. Plückthun, P. Pack
    • Chemistry, Medicine
    • Immunotechnology : an international journal of immunological engineering
    • 1997
    • 318
    • PDF
    Construction, expression, and activity of a bivalent bispecific single-chain antibody.
    • 107
    • PDF